<p>In this episode, Dr Ashleigh Hull and Dr Stephen Tronchin join host Liz Williams to explore theranostics — a cutting-edge approach to cancer treatment that uses radiopharmaceuticals to both detect and treat cancers from within the body. They cover the science behind how these treatments are designed to target cancer cells, which cancers theranostics is already being used for, and the real-world supply chain challenges that determine how many patients can access these therapies. The episode closes with a look at what's on the horizon for the field in Australia and globally.</p><p>Dr Ashleigh Hull is a nuclear medicine technologist and lecturer in medical physics, and Dr Stephen Tronchin is a post-doctoral research fellow. Both work at <a target="_blank" rel="noopener noreferrer nofollow" href="https://adelaide.edu.au">Adelaide University</a> and are part of <a target="_blank" rel="noopener noreferrer nofollow" href="https://radinnovate.au">Radinnovate</a>, an Australian Research Council Industrial Transformation Training Center focused on developing the next generation of nuclear and radiation science researchers for Australia.</p><p><strong>Credits</strong></p><p>Guests: <a target="_blank" rel="noopener noreferrer nofollow" href="https://adelaide.edu.au/people/ashleigh.hull">Ashleigh Hull</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://researchers.adelaide.edu.au/profile/stephen.tronchin">Stephen Tronchin</a></p><p>Host: <a target="_blank" rel="noopener noreferrer nofollow" href="https://researchportalplus.anu.edu.au/en/persons/elizabeth-williams-2/">Elizabeth Williams</a></p><p>Audio Producer: Martin Franklin (<a target="_blank" rel="noopener noreferrer nofollow" href="https://eastcoaststudio.com.au">East Coast Studio</a>)</p><p><strong>Show notes</strong></p><p>Stephen wanted to clarify that beta particles have a range of 1-10 mm in tissue.</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://portal.ahpra.gov.au/s/approved-programs-of-study">Places to study to become a nuclear medicine technologist in Australia</a></p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://mtpconnect.org.au/from-mines-to-medicines-australias-radiopharmaceuticals-future/">Mines to Medicines</a></p><p><strong>Acknowledgements</strong></p><p>Thank you to Eva Bezak for introducing me to Ash and Stephen. ANU is one of the university partners involved in Radinnovate.</p><p><strong>The usual end matter</strong></p><p>Nuclear Matters is a production of the Australian National University College of Systems and Society and the ANU Nuclear Stewardship Network. We acknowledge the Traditional Owners of the lands on which this podcast is being recorded on or listened to, and pay our respects to their Elders – and all First Nations people.</p><p>If you want to send us some feedback on an episode, email us at <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:[email protected]">[email protected]</a>.</p><p>Keep in mind that this podcast is intended for information and education only. In particular, nothing in this episode is intended to serve as medical advice - please consult a qualified medical practitioner.</p><p>The views and opinions expressed in each episode are those of the individual speakers and do not represent the official policy or position of the Australian National University <a target="_blank" rel="noopener nofollow" href="https://systems.anu.edu.au/">College of Systems and Society</a> or the University as a whole.</p>